XML 122 R94.htm IDEA: XBRL DOCUMENT v3.25.0.1

Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail)	1 Months Ended		12 Months Ended
	Jan. 31, 2024	Nov. 30, 2018	Dec. 31, 2024
Ascendis Pharma GmbH [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma GmbH
Ownership			100.00%
Ascendis Pharma Endocrinology GmbH [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Endocrinology GmbH
Ownership			100.00%
Ascendis Pharma, Inc [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma, Inc.
Ownership			100.00%
Ascendis Pharma Endocrinology, Inc. [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Endocrinology, Inc.
Ownership			100.00%
Ascendis Pharma Ophthalmology Division A/S [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Ophthalmology Division A/S
Ownership			100.00%
Ascendis Pharma Endocrinology Division A/S [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Endocrinology Division A/S
Ownership			100.00%
Ascendis Pharma Bone Diseases A/S [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Bone Diseases A/S
Ownership			100.00%
Ascendis Pharma Growth Disorders A/S [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Growth Disorders A/S
Ownership			100.00%
Ascendis Pharma Oncology Division AS [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Oncology Division A/S
Ownership			100.00%
Ascendis Pharma Europe A/S [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Europe A/S
Ownership			100.00%
Ascendis Pharma UK Limited [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma UK Limited
Ownership			100.00%
Ascendis Pharma Iberia S.L. [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Iberia S.L.
Ownership			100.00%
Ascendis Pharma France SASU [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma France SASU
Ownership			100.00%
Ascendis Pharma Italia SRL [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Italia SRL
Ownership			100.00%
Ascendis Pharma Sverige AB [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Sverige AB
Ownership			100.00%
Ascendis Pharma Switzerland GmbH [member]
Disclosure of subsidiaries [line items]
Company			Ascendis Pharma Switzerland GmbH
Ownership			100.00%
VISEN
Disclosure of subsidiaries [line items]
Company			VISEN Pharmaceuticals
Ownership		50.00%	43.90%
Eyconis Inc.
Disclosure of subsidiaries [line items]
Company			Eyconis Inc.
Ownership	41.60%		41.60%

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The name of an associate. [Refer: Total for all associates [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_i&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_i&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 21
-Subparagraph a
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_i&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_NameOfAssociate
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The name of a subsidiary. [Refer: Total for all subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_i&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 12
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_a&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_i&doctype=Standard
-URIDate 2024-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 19B
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_a&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_NameOfSubsidiary
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 21
-Subparagraph a
-Clause iv
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2024-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2024-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2024-01-01
-Paragraph 19B
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOphthalmologyDivisionASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEndocrinologyDivisionASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaBoneDiseaseASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaGrowthDisordersASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaOncologyDivisionAsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaEuropeASMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaUkLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaIberiaSLMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaFranceSasuMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaItaliaSrlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSverigeAbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=asnd_AscendisPharmaSwitzerlandGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_VISENPharmaceuticalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_SignificantInvestmentsInAssociatesAxis=asnd_EyconisIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: